Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02499120 · ClinicalTrials.gov registry record · Phase 2
Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
NCT02499120 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 125 participants.
The verdict
NCT02499120, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the combination of palbociclib with cetuximab is superior to cetuximab in prolonging overall survival in HPV-negative, cetuximab-naive patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Interventions
- DRUG Placebo
- DRUG Cetuximab
- DRUG palbociclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2015-09-10 |
| Est. Completion | 2022-09-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02499120
The ClinicalTrials.gov registry entry for NCT02499120 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02499120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02499120 about?
NCT02499120 is a clinical study titled "Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer". The purpose of this study is to determine whether the combination of palbociclib with cetuximab is superior to cetuximab in prolonging overall survival in HPV-negative, cetuximab-naive patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
What is the current status of trial NCT02499120?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2015-09-10. Estimated completion is 2022-09-07.
What interventions are being tested in trial NCT02499120?
The interventions under investigation include: Placebo (DRUG), Cetuximab (DRUG), palbociclib (DRUG).
Who is sponsoring clinical trial NCT02499120?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.